Amphista Therapeutics nabs $53m Series B

Amphista Therapeutics, a provider of next-generation targeted protein degradation solutions, has secured $53 million in Series B financing.

Amphista Therapeutics, a provider of next-generation targeted protein degradation solutions, has secured $53 million in Series B financing. Forbion and Gilde Healthcare led the round.

Source: Press Release